This highlight presents a recent patent disclosing a series of triazolopyrimidine-derived analogs as inhibitors of glucosylceramide synthase (GCS). The disclosed compounds exhibit potent GCS inhibition, with selected analogs showing picomolar to subnanomolar EC50 values, and are claimed for use in treating diseases and disorders associated with GCS activity. Optimized analogs also demonstrate brain penetration, microsomal stability, and favorable plasma protein binding profiles.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: